44,242 Shares in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Purchased by Rpo LLC

Rpo LLC purchased a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 44,242 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

Several other hedge funds have also bought and sold shares of LXRX. FMR LLC grew its stake in shares of Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after buying an additional 11,179,919 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Lexicon Pharmaceuticals by 8.4% in the third quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock worth $5,534,000 after acquiring an additional 273,436 shares during the last quarter. State Street Corp grew its stake in shares of Lexicon Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock worth $3,880,000 after acquiring an additional 157,738 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Lexicon Pharmaceuticals by 4.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock valued at $2,225,000 after acquiring an additional 58,147 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its position in shares of Lexicon Pharmaceuticals by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 863,255 shares of the biopharmaceutical company’s stock worth $638,000 after purchasing an additional 132,117 shares during the last quarter. Institutional investors own 74.70% of the company’s stock.

Wall Street Analysts Forecast Growth

LXRX has been the topic of several analyst reports. Leerink Partnrs downgraded shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Friday, March 28th. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. StockNews.com started coverage on Lexicon Pharmaceuticals in a research note on Friday, March 28th. They issued a “sell” rating for the company. Finally, Piper Sandler lowered their price target on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $3.67.

Lexicon Pharmaceuticals Trading Up 8.4 %

Shares of LXRX stock opened at $0.50 on Thursday. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.28 and a 1 year high of $2.45. The firm has a fifty day moving average price of $0.59 and a 200-day moving average price of $0.97. The company has a market cap of $123.88 million, a price-to-earnings ratio of -0.67 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $26.55 million during the quarter, compared to analyst estimates of $6.48 million. As a group, equities analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.